Preliminary clinical evaluation of free/total PSA ratio by the IMMULITE® system

International Journal of Biological Markers

Volumn 11, Issue 1, 1996, Pages 24-28

  Correale, M ^a   Pagliarulo, A ^b   Donatuti, G ^c   Sturda F ^c   Capobianco, A M L ^d   Stigliani, V ^d   Rizzello, M ^e   Circhietta, S ^e   Pignatelli, F ^f   Leone, L ^f   Frusciante, V ^g   Modoni, S ^a   Schittulli, F ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c Laboratory of Analysis   (Italy)

^d SAN CARLO HOSPITAL   (Italy)

^e Cardinal Panico Hospital   (Italy)

^f Pignatelli Laboratory   (Italy)

^g CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Benign prostatic hypertrophy; Free PSA; Prostate cancer; PSA ratio

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANALYTIC METHOD; ANIMAL MODEL; ARTICLE; AUTOANALYZER; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY;

ANIMALIA;

EID: 15844409069     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089601100105     Document Type: Article

References (27)

1. Von Kleist S, Bombardieri E, Buraggi G, et al. Immunodiagnosis of tumors. Eur J Cancer 1993; 29A: 1622-30.
2. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860-4.
3. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in 60 years old or older. J Urol 1995; 153: 1160-3.
4. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen. J Urol 1992; 147: 817-21.
5. Nishiya M, Miller GJ, Lookner DH, Crowford ED. Prostate specific antigen density in patients with histologically proven prostate carcinoma. Cancer 1994; 74: 3002-9.
6. Carter HB, Morrel CH, Pearson JD, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992; 52: 3323-8.
7. Katz AE, Olsson CA, Raffo AJ, et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994; 43: 765-75.
8. Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995; 13: 1195-200.
9. Vessela RL, Noteboom J, Lange PH, Rittenhouse H, Liu R, Kusnierz E. Ultrasensitive PSA immunoassay: How low do we need to go? J Urol 1993; 72: 187-9.
10. Yu H, Diamandis EP. Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol 1995; 153: 1004-8.
11. Watt KWK, Lee PJ, M'Timkulu TM, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83: 3166-70.
12. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755-63.
13. Lilja H, Cockett ATK, Abrahamsson PA. Prostate specific antigen predominantly forms a complex with alpha-1-antichymotrypsin in blood. Cancer 1992; 70: 230-4.
14. Panteghini M, Pagani F, Bonora R. Pre-analytical and biological variability of prostatic acid phosphatase and prostate-specific antigen in serum from patients with prostate pathology. Eur J Clin Chem Clin Biochem 1992; 30: 135-9.
15. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989; 264: 11539-42.
16. Graves H. Standardization of immunoassay for prostate-specific antigen. Cancer 1993; 72: 3141-4.
17. Nakamura RM. Current and future directions regarding quality assurance and standardization of prostate specific antigen immunoassays. Cancer 1994; 74: 1655-9.
18. Murphy GP. The Second Stanford Conference on International Standardization of Prostate Specific Antigen Assays. Cancer 1995; 75: 122-8.
19. Stamey TA. Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. Urology 1995; 45: 173-84.
20. Christensson A, Bjork T, Nilsson O, et al. Serum prostate-specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-5.
21. Leinonen J, Lovgren T, Vornnen T, Stenman UH. Double-label time-resolved immunofluorimetric assay of prostate-specific antigen and of its complex with alpha-1-antichymotrypsin. Clin Chem 1993; 39: 2098-103.
22. Prestigiacomo AF, Stamey TA. Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest 1995; 55: 32-4.
23. Vessela RL. Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity. Clin Chem 1993; 39: 2035-9.
24. Babson AL. The Immulite Automated Immunoassay System. J Clin Immunoassay 1991; 14: 83-8.
25. Whiterspoon LR. Very sensitive PSA measurements by chemiluminescent immunoassays (IMMULITE). Clin Chem 1994; 40: 105.
26. Benson MC, Olsson CA. Pro state-specific antigen and prostate specific antigen density. Cancer 1994; 74: 1667-73.
27. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61.